+

WO2001019798A3 - Inhibiteurs du facteur xa - Google Patents

Inhibiteurs du facteur xa Download PDF

Info

Publication number
WO2001019798A3
WO2001019798A3 PCT/US2000/025195 US0025195W WO0119798A3 WO 2001019798 A3 WO2001019798 A3 WO 2001019798A3 US 0025195 W US0025195 W US 0025195W WO 0119798 A3 WO0119798 A3 WO 0119798A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
heterocyclic ring
ring system
compounds
factor
Prior art date
Application number
PCT/US2000/025195
Other languages
English (en)
Other versions
WO2001019798A2 (fr
Inventor
Bing-Yan Zhu
Zhaozhong Jon Jia
Wenrong Huang
Yonghong Song
James Kanter
Robert M Scarborough
Original Assignee
Cor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU74866/00A priority Critical patent/AU781880B2/en
Priority to JP2001523378A priority patent/JP2003509412A/ja
Priority to EP00963451A priority patent/EP1216231A2/fr
Priority to BR0014078-3A priority patent/BR0014078A/pt
Priority to MXPA02002762 priority patent/MX228790B/es
Priority to IL14869800A priority patent/IL148698A0/xx
Application filed by Cor Therapeutics Inc filed Critical Cor Therapeutics Inc
Priority to CA002385589A priority patent/CA2385589A1/fr
Priority to NZ517828A priority patent/NZ517828A/en
Priority to HU0203954A priority patent/HUP0203954A2/hu
Publication of WO2001019798A2 publication Critical patent/WO2001019798A2/fr
Publication of WO2001019798A3 publication Critical patent/WO2001019798A3/fr
Priority to NO20021230A priority patent/NO20021230L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/40—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Facsimile Image Signal Circuits (AREA)
  • Controls And Circuits For Display Device (AREA)
  • Dot-Matrix Printers And Others (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne de nouveaux composés, leurs sels et des compositions les contenant, efficaces contre le facteur Xa mammalien. Ces composés sont utilisés i∫i⊃n vivo∫/i⊃ et ∫i⊃in vitro∫/i⊃ pour prévenir ou traiter les troubles de la coagulation.
PCT/US2000/025195 1999-09-17 2000-09-15 INHIBITEURS DU FACTEUR Xa WO2001019798A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
JP2001523378A JP2003509412A (ja) 1999-09-17 2000-09-15 Ｘａ因子阻害剤
EP00963451A EP1216231A2 (fr) 1999-09-17 2000-09-15 INHIBITEURS DU FACTEUR Xa
BR0014078-3A BR0014078A (pt) 1999-09-17 2000-09-15 Inibidores de fator xa
MXPA02002762 MX228790B (es) 1999-09-17 2000-09-15 Inhibidores del factor xa.
IL14869800A IL148698A0 (en) 1999-09-17 2000-09-15 INHIBITORS OF FACTOR Xa
AU74866/00A AU781880B2 (en) 1999-09-17 2000-09-15 Inhibitors of factor Xa
CA002385589A CA2385589A1 (fr) 1999-09-17 2000-09-15 Inhibiteurs du facteur xa
NZ517828A NZ517828A (en) 1999-09-17 2000-09-15 Inhibitors having activity against mammalian factor Xa
HU0203954A HUP0203954A2 (hu) 1999-09-17 2000-09-15 Xa faktor inhibitorok
NO20021230A NO20021230L (no) 1999-09-17 2002-03-12 Faktor Xa inhibitorer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15433299P 1999-09-17 1999-09-17
US60/154,332 1999-09-17

Publications (2)

Publication Number Publication Date
WO2001019798A2 WO2001019798A2 (fr) 2001-03-22
WO2001019798A3 true WO2001019798A3 (fr) 2001-10-25

Family

ID=22550934

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/025195 WO2001019798A2 (fr) 1999-09-17 2000-09-15 INHIBITEURS DU FACTEUR Xa

Country Status (16)

Country Link
EP (1) EP1216231A2 (fr)
JP (1) JP2003509412A (fr)
CN (1) CN1390206A (fr)
AU (1) AU781880B2 (fr)
BR (1) BR0014078A (fr)
CA (1) CA2385589A1 (fr)
CZ (1) CZ2002959A3 (fr)
HU (1) HUP0203954A2 (fr)
IL (1) IL148698A0 (fr)
MX (1) MX228790B (fr)
NO (1) NO20021230L (fr)
NZ (1) NZ517828A (fr)
RU (1) RU2002110295A (fr)
TR (1) TR200201413T2 (fr)
WO (1) WO2001019798A2 (fr)
ZA (4) ZA200202117B (fr)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142959A0 (en) 1998-12-23 2002-04-21 Du Pont Pharm Co Nitrogen containing heterobicycles as factor xa inhibitors
AU776053B2 (en) 2000-03-31 2004-08-26 Astellas Pharma Inc. Diazepan derivatives or salts thereof
TWI288745B (en) 2000-04-05 2007-10-21 Daiichi Seiyaku Co Ethylenediamine derivatives
WO2002010154A2 (fr) 2000-07-27 2002-02-07 Eli Lilly And Company Amides heterocycliques substitues
HUP0400558A3 (en) 2000-11-22 2010-03-29 Astellas Pharma Inc Substituted benzene derivatives or salts thereof and pharmaceutical compositions containing them
AU2001297648A1 (en) 2000-11-28 2002-08-28 Eli Lilly And Company Substituted carboxamides as inhibitors of factor xa
US6998408B2 (en) 2001-03-23 2006-02-14 Bristol-Myers Squibb Pharma Company 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors
WO2002085353A1 (fr) * 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-ones utilisees comme inhibiteurs du facteur xa
CA2444571A1 (fr) 2001-04-18 2002-10-31 Bristol-Myers Squibb Company 1, 4, 5, 6-tetrahydropyrazolo-¬3, 4-c|-pyridine-7-ones comme inhiteurs du facteur xa
AU2002310070A1 (en) 2001-05-22 2002-12-03 Bristol-Myers Squibb Company Bicyclic inhibitors of factor xa
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
TWI331526B (en) 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
JP4249621B2 (ja) 2001-09-21 2009-04-02 ブリストル−マイヤーズ スクイブ カンパニー 第Ｘａ因子阻害剤としてのラクタム含有化合物およびその誘導体
US7030141B2 (en) 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
AU2002350217A1 (en) 2001-12-04 2003-06-17 Bristol-Myers Squibb Company Glycinamides as factor xa inhibitors
US7449457B2 (en) 2001-12-07 2008-11-11 Eli Lilly And Company Substituted heterocyclic carboxamides with antithrombotic activity
EP1505966A4 (fr) 2002-05-10 2006-08-30 Bristol Myers Squibb Co Derives cycloalkyles 1,1-disubstitues utilises en tant qu'inhibiteurs du facteur xa
AU2003248549B2 (en) 2002-05-24 2010-04-08 Millennium Pharmaceuticals, Inc. CCR9 inhibitors and methods of use thereof
PL375527A1 (en) * 2002-06-29 2005-11-28 Zentaris Gmbh Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
US7741519B2 (en) 2007-04-23 2010-06-22 Chemocentryx, Inc. Bis-aryl sulfonamides
US7227035B2 (en) 2002-11-18 2007-06-05 Chemocentryx Bis-aryl sulfonamides
EP2256116A3 (fr) 2002-11-18 2011-11-16 ChemoCentryx, Inc. Arylsulfonamides
EP2982668A3 (fr) 2002-12-03 2016-04-13 Pharmacyclics LLC Dérivés de 2-(2-hydroxybiphényl-3-yl)-1h-benzoimidazole-5-carboxamidine en tant qu'inhibiteurs du facteur viia inhibitors pour le traitement de maladies thromboemboliques
DE60329529D1 (de) * 2002-12-23 2009-11-12 Sanofi Aventis Deutschland Pyrazolderivate als faktor-xa-inhibitoren
EP1433788A1 (fr) * 2002-12-23 2004-06-30 Aventis Pharma Deutschland GmbH Dérivés de pyrazole en tant qu'inhibiteurs du facteur Xa
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479678A1 (fr) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Derivés du pyrazole en tant qu'inhibiteurs du facteur Xa
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
US7696225B2 (en) 2003-01-06 2010-04-13 Osi Pharmaceuticals, Inc. (2-carboxamido)(3-Amino) thiophene compounds
CA2515119A1 (fr) 2003-02-07 2004-08-19 Daiichi Pharmaceutical Co., Ltd. Derive de pyrazole
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US20040220170A1 (en) * 2003-05-01 2004-11-04 Atkinson Robert N. Pyrazole-amides and sulfonamides as sodium channel modulators
EP1620405A2 (fr) * 2003-05-01 2006-02-01 Abbott Laboratories Pyrazole-amides et sulfonamides modulateurs des canaux sodiques
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
EP1651612B9 (fr) 2003-07-22 2012-09-05 Astex Therapeutics Limited Composes 1h-pyrazole 3,4-disubstitues et leur utilisation en tant que kinases dependant des cyclines (cdk) et modulateurs de la glycogene synthase kinase-3 (gsk-3)
SE0302573D0 (sv) 2003-09-26 2003-09-26 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
EP1680109A4 (fr) 2003-10-07 2009-05-06 Renovis Inc Derives d'amide utilises comme ligands du canal ionique et compositions pharmaceutiques et methodes d'utilisation de ces derives
MXPA06007326A (es) 2003-12-23 2007-01-26 Astex Therapeutics Ltd Derivados de pirazol como moduladores de proteina cinasa.
AU2005223483B2 (en) 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275181A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
AU2005275182A1 (en) 2004-07-22 2006-02-23 Ptc Therapeutics, Inc. Thienopyridines for treating Hepatitis C
RU2007101488A (ru) 2004-08-03 2008-09-10 Вайет (Us) Индазолы для лечения сердечно-сосудистых заболеваний
EP1799668A1 (fr) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant que modulateurs de stearoyle-coa desaturase
EP1799664A1 (fr) 2004-09-20 2007-06-27 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'inhibiteurs de la stearoyl-coa desaturase
BRPI0515505A (pt) 2004-09-20 2008-07-29 Xenon Pharmaceuticals Inc derivados heterocìclicos e sua utilização como inibidores da estearoil-coa desaturase
AR051094A1 (es) 2004-09-20 2006-12-20 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EP2289510A1 (fr) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Dérivés hétérocycliques pour le traitement des maladies induites par des enzymes stearoyl-coa desaturase
WO2006101521A2 (fr) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation en tant qu'agents therapeutiques
WO2006034279A1 (fr) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Derives heterocycliques et leur utilisation comme agents therapeutiques
BRPI0515897A (pt) 2004-09-24 2008-08-12 Astrazeneca Ab composto, uso do mesmo, composição farmacêutica, e, método para a terapia de dor em um animal de sangue quente, e para a preparação de um composto
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
EP1833819A1 (fr) 2004-12-30 2007-09-19 Astex Therapeutics Limited Composes de pyrazole regulant l`activite de kinases cdk, gsk et aurora
TWI441819B (zh) 2005-01-07 2014-06-21 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之化合物
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
KR101346886B1 (ko) 2005-01-21 2014-01-02 아스텍스 테라퓨틱스 리미티드 제약 화합물
CA2594474C (fr) 2005-01-21 2016-03-29 Astex Therapeutics Limited Composes pharmaceutiques
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
ATE443056T1 (de) 2005-03-10 2009-10-15 Pfizer Substituierte n-sulfonylaminophenylethyl-2- phenoxyacetamidverbindungen
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
EP1902032A1 (fr) 2005-06-22 2008-03-26 Astex Therapeutics Limited Composes pharmaceutiques
EP1933832A2 (fr) 2005-06-23 2008-06-25 Astex Therapeutics Limited Combinaisons pharmaceutiques comprenant des derives de pyrazole en tant que modulateurs de proteine kinase
US7781460B2 (en) 2005-09-05 2010-08-24 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-IV
WO2007031838A1 (fr) 2005-09-16 2007-03-22 Ranbaxy Laboratories Limited Pyrazolo[3,4-b]pyridines substituees en tant qu'inhibiteurs de la phosphodiesterase
GB0521244D0 (en) 2005-10-19 2005-11-30 Astrazeneca Ab Benzamide compounds
WO2007077435A1 (fr) 2005-12-30 2007-07-12 Astex Therapeutics Limited Composes pharmaceutiques
TW200745049A (en) 2006-03-23 2007-12-16 Astrazeneca Ab New crystalline forms
TW200808769A (en) 2006-04-18 2008-02-16 Astrazeneca Ab Therapeutic compounds
ES2444695T3 (es) 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
JP5523829B2 (ja) 2006-06-29 2014-06-18 アステックス、セラピューティックス、リミテッド 複合薬剤
MX2009004314A (es) 2006-11-13 2009-05-05 Pfizer Prod Inc Diaril, dipiridinil y arilpiridinilderivados y usos de los mismos.
US20080207659A1 (en) 2007-02-15 2008-08-28 Asit Kumar Chakraborti Inhibitors of phosphodiesterase type 4
GB0704932D0 (en) 2007-03-14 2007-04-25 Astex Therapeutics Ltd Pharmaceutical compounds
KR101473207B1 (ko) * 2007-04-13 2014-12-16 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｘａ 인자 억제제로서 작용하는 화합물과의 병용 항응고 요법
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP5781932B2 (ja) 2008-11-03 2015-09-24 アレシア・バイオセラピューティクス・インコーポレーテッド 腫瘍抗原の生物活性を特異的にブロックする抗体
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
EP2417123A2 (fr) 2009-04-06 2012-02-15 Agios Pharmaceuticals, Inc. Compositions thérapeutiques et procédés d'utilisation associés
JP2012529432A (ja) 2009-06-05 2012-11-22 リンク・メディスン・コーポレーション アミノピロリジノン誘導体及びその使用
CA2944788C (fr) 2009-06-29 2023-08-22 Agios Pharmaceuticals, Inc. Composes, et compositions associees, qui modulent la pyruvate kinase m2, et methodes de fabrication associees
EP3064595B1 (fr) 2009-10-21 2019-02-27 Agios Pharmaceuticals, Inc. Procédés pour des troubles liés à la prolifération cellulaire
EP3257854A1 (fr) 2009-11-05 2017-12-20 University of Notre Dame du Lac Composés d'imidazo[1,2-a]pyridine, leur synthèse et procédés pour les utiliser
NZ700332A (en) 2010-03-30 2017-06-30 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
CN101870636B (zh) * 2010-04-01 2013-01-23 大唐(杭州)医药化工有限公司 2-溴-6-氟萘的制备方法
EP2651898B1 (fr) 2010-12-17 2015-12-09 Agios Pharmaceuticals, Inc. Nouveaux dérivés de n-(4-(azétidine- 1 - carbonyl) phényl)-(hétéro-) arylsulfonamide en tant que modulateurs de la pyruvate kinase m2 (pmk2)
JP6092118B2 (ja) 2010-12-21 2017-03-08 アジオス ファーマシューティカルズ， インコーポレイテッド ニ環式ｐｋｍ２活性化剤
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
SI3173427T1 (sl) 2011-03-31 2019-08-30 ADC Therapeutics SA, Protitelesa proti antigenu 1, povezanemu z ledvicami, in antigen vezavni fragmenti le-tega
JP6267112B2 (ja) 2011-05-03 2018-01-24 アジオス ファーマシューティカルズ， インコーポレイテッド ピルビン酸キナーゼアクチベーターの使用方法
PL3406251T3 (pl) 2011-05-03 2024-04-29 Agios Pharmaceuticals, Inc. Aktywatory kinazy pirogronianowej do stosowania w terapii
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
EP2802351B1 (fr) 2012-01-09 2019-03-27 ADC Therapeutics SA Agents pour le traitement du cancer du sein triple négatif
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CN103483242A (zh) * 2012-06-15 2014-01-01 上海朴颐化学科技有限公司 4-(2’-吡啶基)苄基肼及其中间体的制备方法
WO2014053968A1 (fr) 2012-10-04 2014-04-10 Pfizer Limited Inhibiteurs de kinase associée à la tropomyosine pyrrolo[3,2-c]pyridine
SG11201506757TA (en) 2013-03-15 2015-09-29 Verseon Corp Halogenopyrazoles as inhibitors of thrombin
CN110179795A (zh) 2013-03-15 2019-08-30 维颂公司 作为丝氨酸蛋白酶抑制剂的多取代芳族化合物的制药用途
WO2015003360A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
WO2015003355A2 (fr) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Composés thérapeutiquement actifs et leurs méthodes d'utilisation
JP6529492B2 (ja) 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
US10266488B2 (en) 2013-10-10 2019-04-23 Eastern Virginia Medical School 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase
US9968595B2 (en) 2014-03-14 2018-05-15 Agios Pharmaceuticals, Inc. Pharmaceutical compositions of therapeutically active compounds
US9914704B2 (en) * 2014-06-11 2018-03-13 Bayer Cropscience Aktiengesellschaft Process for preparing 3,5-bis(haloalkyl)pyrazoles via acylation of ketimines
CN104016944B (zh) * 2014-06-16 2016-05-18 山东大学 N-(2-(胺甲基)苯基)噻唑-4-甲酰胺衍生物及其制备方法与应用
CA2960790A1 (fr) 2014-09-17 2016-03-24 Verseon Corporation Composes de pyridone substituee par pyrazolyl en tant qu'inhibiteurs de serine protease
BR112017018092A2 (pt) 2015-02-27 2018-04-10 Verseon Corp composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio.
US11234976B2 (en) 2015-06-11 2022-02-01 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
WO2016202756A1 (fr) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Composés 2-(1h-pyrazol-1-yl)-1h-benzimidazole substitués
KR20180053386A (ko) 2015-09-17 2018-05-21 마빈 제이. 밀러 마이코박테리아 감염에 대해 유용한 벤질 아민-함유 헤테로사이클릭 화합물 및 조성물
EP4403173A3 (fr) 2015-10-15 2024-10-09 Les Laboratoires Servier Polythérapie pour le traitement de tumeurs malignes
WO2017066571A1 (fr) 2015-10-15 2017-04-20 Agios Pharmaceuticals, Inc. Polythérapie pour le traitement de tumeurs malignes
EA202090871A1 (ru) 2017-10-06 2020-07-03 Форма Терапьютикс, Инк. Ингибирование убиквитин-специфической пептидазы 30
TWI796596B (zh) 2018-02-13 2023-03-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN112041311B (zh) 2018-04-19 2023-10-03 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102596598B1 (ko) 2018-04-26 2023-11-03 화이자 인코포레이티드 사이클린 의존성 키나제 억제제로서 2-아미노-피리딘 또는 2-아미노-피리미딘 유도체
KR20210010887A (ko) 2018-05-17 2021-01-28 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 펩티다제 30 억제제로서 유용한 융합된 비시클릭 화합물
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
TWI732245B (zh) 2018-07-13 2021-07-01 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
RS64321B1 (sr) 2018-10-05 2023-08-31 Forma Therapeutics Inc Fuzionisani pirolini koji se ponašaju kao inhibitori ubikvitin specifične proteaze 30 (usp30)
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
FI3986890T3 (fi) 2019-06-18 2024-01-15 Pfizer Bentsisoksatsolisulfonamidijohdannaisia
EP4506001A3 (fr) 2019-12-06 2025-04-30 Vertex Pharmaceuticals Incorporated Tetrahydrofurannes substitués comme modulateurs des canaux sodiques
CN117794920A (zh) 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 N-(羟烷基(杂)芳基)四氢呋喃甲酰胺作为钠通道调节剂
KR20240024818A (ko) 2021-06-21 2024-02-26 신액트 파마 에이피에스 페닐 피롤 아미노구아니딘 염 및 제형

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028269A1 (fr) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company COMPOSES HETEROAROMATIQUES CONTENANT DE L'AZOTE, UTILISES EN TANT QU'INHIBITEURS DU FACTEUR Xa
WO1998028282A2 (fr) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGENE OU SOUFRE CONTANANT DES HETERO-AROMATIQUES UTILISES COMME INHIBITEURS DU FACTEUR Xa
WO1998057934A1 (fr) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Agents aromatiques a six membres amidino utiles en tant qu'inhibiteurs du facteur xa

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028269A1 (fr) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company COMPOSES HETEROAROMATIQUES CONTENANT DE L'AZOTE, UTILISES EN TANT QU'INHIBITEURS DU FACTEUR Xa
WO1998028282A2 (fr) * 1996-12-23 1998-07-02 Du Pont Pharmaceuticals Company OXYGENE OU SOUFRE CONTANANT DES HETERO-AROMATIQUES UTILISES COMME INHIBITEURS DU FACTEUR Xa
WO1998057934A1 (fr) * 1997-06-19 1998-12-23 The Du Pont Merck Pharmaceutical Company Agents aromatiques a six membres amidino utiles en tant qu'inhibiteurs du facteur xa

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Dictionary of Organic Compounds, 5th Ed., Vol. 5", 1982, CHAPMAN AND HALL, NEW YORK, US, XP002161122, 157909 *
H. SUZUKI, ET AL.: "Selective reduction with lithium aluminium hydride / diphosphorus tetraiodide. A mild conversion of aromatic ketones to parent hydrocarbons", CHEMISTRY LETTERS, no. 6, June 1983 (1983-06-01), Chemical Society of Japan, Tokyo, JP, pages 909 - 910, XP002161110, ISSN: 0366-7022 *
H.J SPIE, ET AL.: "An improved synthesis of aryl sulphones", SYNTHESIS, no. 3, March 1984 (1984-03-01), Georg Thieme Verlag, Stuttgart, DE, pages 283 - 284, XP002161121, ISSN: 0039-7881 *
Q.-Y. CHEN, ET AL.: "Photo-induced electron-transfer reaction of aryl perfluoroalkanesulphonates with anilines", JOURNAL OF FLUORINE CHEMISTRY, vol. 66, no. 1, January 1994 (1994-01-01), Elsevier Science Publishers, Amsterdam, NL, pages 59 - 62, XP002161119, ISSN: 0022-1139 *
T. KEUMI, ET AL.: "2-(Trifluoromethylsulphonyloxy)pyridine as a reagent for the ketone synthesis from carboxylic acids and aromatic hydrocarbons", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 61, no. 2, February 1988 (1988-02-01), Japan Publications Trading Co., Tokyo JP, pages 455 - 459, XP002161120, ISSN: 0009-2673 *

Also Published As

Publication number Publication date
CN1390206A (zh) 2003-01-08
RU2002110295A (ru) 2003-12-10
MXPA02002762A (es) 2003-10-14
NO20021230L (no) 2002-05-21
NZ517828A (en) 2003-10-31
HUP0203954A2 (hu) 2003-03-28
AU781880B2 (en) 2005-06-16
ZA200202116B (en) 2004-02-10
CZ2002959A3 (cs) 2002-07-17
WO2001019798A2 (fr) 2001-03-22
EP1216231A2 (fr) 2002-06-26
AU7486600A (en) 2001-04-17
IL148698A0 (en) 2002-09-12
ZA200202117B (en) 2004-02-25
ZA200306488B (en) 2004-04-28
TR200201413T2 (tr) 2003-02-21
ZA200306490B (en) 2004-05-26
JP2003509412A (ja) 2003-03-11
BR0014078A (pt) 2002-12-31
CA2385589A1 (fr) 2001-03-22
NO20021230D0 (no) 2002-03-12
MX228790B (es) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2001019798A3 (fr) Inhibiteurs du facteur xa
WO2000071511A3 (fr) INHIBITEURS DU FACTEUR Xa
WO2001019788A3 (fr) BENZAMIDES ET INHIBITEURS CORRESPONDANTS DU FACTEUR Xa
WO2000047554A3 (fr) INHIBITEURS DU FACTEUR Xa
WO2000071493A3 (fr) INHIBITEURS DU FACTEUR Xa
WO1998016523A3 (fr) Inhibiteurs competitifs du facteur xa
WO2001064642A3 (fr) Benzamides et inhibiteurs connexes du facteur xa
WO2000071516A3 (fr) INHIBITEURS DU FACTEUR Xa
WO2001056989A3 (fr) Inhibiteurs du facteur xa contenant du phenylene bivalent
ATE368643T1 (de) Faktor xa benzamidin inhibitoren
WO2001072708A3 (fr) INHIBITEURS D'OXINIDOLE DU FACTEUR Xa
WO2001057021A3 (fr) 2-[1H]-QUINOLONE ET 2-[1H]-QUINOXALONE INHIBITEURS DU FACTEUR Xa
MY128323A (en) Thiazole derivatives for inhibition of cytokine production and of cell adhesion
ATE219085T1 (de) 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
WO2002006280A3 (fr) Inhibiteurs du facteur xa
NZ515278A (en) Halo derivatives of 9-deoxo-9a-aza-9a- homerythromycin A their salts and preparation process
DE60027204D1 (en) Benzamidinderivate
AU1847401A (en) Diketopiperazine derivatives to inhibit thrombin

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 74866/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002/02117

Country of ref document: ZA

Ref document number: 148698

Country of ref document: IL

Ref document number: PA/a/2002/002762

Country of ref document: MX

Ref document number: 200202117

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2002-959

Country of ref document: CZ

Ref document number: 2385589

Country of ref document: CA

Ref document number: 517828

Country of ref document: NZ

ENP Entry into the national phase

Ref document number: 2001 523378

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027003603

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2000963451

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2002 2002110295

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2002/478/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 00815757X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002/01413

Country of ref document: TR

WWP Wipo information: published in national office

Ref document number: 1020027003603

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000963451

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-959

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 517828

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 517828

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 74866/00

Country of ref document: AU

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载